$8.09 0.00 (0.00%)
Oculis Holding AG Warrants (OCSAW)
Company News
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
Oculis presented positive Phase 2 trial results for Privosegtor, showing improved visual acuity and preservation of retinal ganglion cells in acute optic neuritis patients at the ECTRIMS 2025 Congress.